BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ElexoPharm Receives € 2.1 Million EUROSTARS Grant for Program Targeting Mitochondrial Diseases


5/21/2012 9:01:52 AM

Saarbruecken, Germany, May 21, 2012 / B3C newswire / - A EUROSTARS grant of €2.1 million has been awarded to a transnational consortium consisting of Khondrion BV ( Nijmegen), Radboud University Nijmegen Medical Centre (RUNMC, Nijmegen), Pharmacelsus GmbH (Saarbruecken) and ElexoPharm GmbH (Saarbruecken). This grant, which for the German partners comes from the German Federal Ministry of Education and Research (BMBF), will support an ambitious scientific collaboration to discover treatments for mitochondrial diseases with high unmet medical need (approximately 300,000 patients in industrialized countries).

During the three years’ grant period, each partner of this multidisciplinary European consortium will contribute its expertise to reach their shared goal. ElexoPharm is responsible for the design and synthesis of small pharmaceutical molecules with state of the art in silico modelling and medicinal chemistry technologies. Khondrion acts as the consortium leader and will carry out the in vitro evaluation of the new chemical entities, including screening in their cell-based mitochondrial disease models. Pharmacelsus is going to perform ADME, toxicity and PK studies in their GLP-certified facilities, and the RUNMC will evaluate the best compounds regarding in vivo efficacy in preclinical studies to achieve Proof of Principle. "ElexoPharm is very proud to have received this prestigious transnational grant to develop medicines to treat these diseases of high medical need. It is a further recognition of the excellent drug discovery capabilities of our growing company", states Axel Koch, managing director of ElexoPharm.

About ElexoPharm

ElexoPharm GmbH is a German biotech company located in Saarbrücken, founded as a spin-off of the Department of Pharmaceutical and Medicinal Chemistry of Saarland University headed by Professor Rolf Hartmann. ElexoPharm is focused on the preclinical discovery and optimization of novel innovative drugs for human diseases, which are currently not or insufficiently treatable with existing drugs. The largest success of ElexoPharm was the execution of an exclusive license and collaboration agreement with Merck & Co. Inc. for one of its own research projects (development of aldosterone synthase inhibitors for the treatment of cardiovascular diseases) in 2010.

Contact

Axel Koch, MBA

Managing Director

ElexoPharm GmbH

Im Stadtwald

A1.1,

66123 Saarbruecken

Germany

Phone: +49 (0) 681 - 302 68320

Fax: +49 (0) 681 - 910 2894

Email: info@elexopharm.de

URL: www.elexopharm.de



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES